Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4 Mln
Revenue (TTM)
$45 Mln
Net Profit (TTM)
$-36 Mln
ROE
-17.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
203.2
Industry P/E
--
EV/EBITDA
0.3
Div. Yield
0 %
Debt to Equity
-0.1
Book Value
$--
EPS
$-3.2
Face value
--
Shares outstanding
5,112,885
CFO
$-356.83 Mln
EBITDA
$-366.34 Mln
Net Profit
$-427.83 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Redhill Biopharma - ADR
| -22.4 | -17.6 | -22.4 | -68.7 | -93.2 | -91.6 | -72.3 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Redhill Biopharma - ADR
| -83.4 | -99.3 | -74.0 | -94.6 | -68.1 | 33.1 | 9.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Redhill Biopharma - ADR
|
0.8 | 3.8 | 8.0 | -8.3 | -30.0 | 632.6 | -- | 203.2 |
| 9.2 | 2,179.2 | 510.2 | 146.9 | 37.2 | 35.6 | 15.5 | 4.6 | |
| 12.5 | 3,812.0 | 3,018.8 | 72.1 | 12.6 | -80 | 54.3 | 86.1 | |
| 168.5 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 73.2 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.5 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.3 | 11,237.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.7 | 2.9 | |
| 23.1 | 11,653.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.2 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the... treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel. Address: 21 Ha?arba?a Street, Tel Aviv-Yafo, Israel, 6473921 Read more
Co-Founder, Chairman & CEO
Mr. Dror Ben-Asher
Co-Founder, Chairman & CEO
Mr. Dror Ben-Asher
Headquarters
Tel Aviv-Yafo
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Redhill Biopharma Ltd - ADR is $0.80 (NASDAQ) as of 02-Apr-2026 16:28 EDT. Redhill Biopharma Ltd - ADR has given a return of -93.21% in the last 3 years.
Since, TTM earnings of Redhill Biopharma Ltd - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.94
|
-3.42
|
|
2023
|
0.03
|
0.39
|
|
2022
|
0.00
|
0.00
|
|
2021
|
0.00
|
0.03
|
|
2020
|
-0.01
|
0.04
|
The 52-week high and low of Redhill Biopharma Ltd - ADR are Rs 3.31 and Rs 0.71 as of 03-Apr-2026.
Redhill Biopharma Ltd - ADR has a market capitalisation of $ 4 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Redhill Biopharma Ltd - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.